Amgen (AMGN) announced that the global Phase 3 DeLLphi-304 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM – Research Report) and Amgen (AMGN – Research ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on ...

The global US Autoinjectors Market is projected to expand to a value of US$1.45 billion in 2030 from US$0.65 billion in 2024, with a significant ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Thrivent Financial for Lutherans lessened its holdings in shares of The Hanover Insurance Group, Inc. (NYSE:THG – Free Report) by 17.8% in the fourth quarter, HoldingsChannel reports.

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers hope ...